Robert Bryant, PhD, of Australia-based University of Adelaide, and colleagues examined 246 ulcerative colitis patients treated with the “Treat to Target” approach in a multicenter, retrospective, cross-sectional review of patients. Researchers recorded clinical and objective assessments of disease activity.
Here’s what they found:
1. Sixty-one percent of ulcerative colitis patients were in clinical readmission.
2. Thirty-five percent were in clinical and endoscopic remission.
3. Sixteen percent were in concordant clinical, endoscopic and histological remission.
4. Clinician-related factors affected outcomes at a higher rate than disease-related factors.
5. Physicians used C-reactive protein more than endoscopy as a biomarker of disease activity.
Researchers concluded, “Most patients with UC do not achieve composite clinical and endoscopic remission in ‘real-world’ practice. Clinician uptake of proposed ‘Treat to Target’ guidelines is a challenge to their implementation.”
More articles on gastroenterology:
7 patients with intragastric balloon systems die from adverse events
Florida jury finds gastroenterologist not liable in alleged ‘slapdash colonoscopy’ trial
How effective is fecal immunochemical testing for colorectal cancer?
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.